Brands
Caltex Lubricants signs ace cricketer Ravindra Jadeja as its brand ambassador
Mumbai: Caltex Lubricants is pleased to announce the appointment of the ace Indian cricketer, Ravindra Jadeja, as the brand’s ambassador. Through this strategic endorsement, the brand aims to leverage Jadeja’s popularity in the sport of cricket to enhance the visibility of Caltex Lubricants across India, with the brand’s tagline, ‘Caltex Yaani Commitment’.
Caltex Lubricants is marketed by HPCL in India through the licensing agreement with Chevron Brand International LLC. Caltex’s heritage, global recognition, and cutting-edge technology performance sets it apart as one of the world’s leading oil and gas brands.
Ravindra Jadeja is known for his exceptional on-field skills and was at the top of his game during the 2023 Cricket World Cup. His unwavering commitment to the game of cricket resonates perfectly with Caltex Lubricants’ promise of superior quality, performance, and reliability. Jadeja will now front a series of marketing campaigns to promote Caltex’s premium products while emphasizing the importance of high-quality lubricants for vehicles and machinery. Caltex Lubricants in India includes Chevron’s proprietary Havoline and Delo branded lubricant products.
Chevron International Products (IP)general manager, marketing and sales support Marc Bouchebl said, “We are excited to welcome Ravindra Jadeja as the Caltex Lubricants brand ambassador in India. His passion, dedication for the game and success story align seamlessly with the values the Caltex brand upholds. With his support, we aim to reach a wider audience across India and reinforce Caltex’s position as the all-rounder lubricants provider for our customers.”
Ravindra Jadeja expressed his enthusiasm about the partnership, stating, “I am excited to be associated with Caltex, a brand that stands for commitment and its all-around abilities. I look forward to build recognition for Caltex Lubricants and their unmatched performance, encouraging consumers to make the right choice for their vehicles.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
